This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT00203970
First received: September 12, 2005
Last updated: August 28, 2017
Last verified: August 2017
September 12, 2005
August 28, 2017
February 2001
March 2001   (Final data collection date for primary outcome measure)
retrospective chart review to determine how patients with deep venous thromboses or pulmonary emboli were treated when hospitalized on the medicine services [ Time Frame: June 1997 to December 2000 ]
Using the data abstraction form, we gathered the following information: 1) patient demographics, 2) the identity of the attending, resident, and intern caring for the patient, 3) whether the patient had any absolute or relative contraindications for receiving LMWH, as delineated by the DVT critical pathway, including insurance status and 4) how the patient was treated for his/her condition.
Not Provided
Complete list of historical versions of study NCT00203970 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services
The purpose of this research is to gain insight into the way in which physicians adopt new practice techniques. In particular, we are interested in how medical innovations diffuse throughout social networks. We wish to examine the diffusion of Low Molecular Weight Heparin (LMWH) use for Deep Vein Thrombosis (DVT) throughout the social network of general internal medicine interns, residents, and attendings at the University of Chicago Hospital. In numerous clinical trials, LMWH has been demonstrated to be as effective as unfractionated heparin as a bridge to long-term anticoagulation therapy with Coumadin, with the added benefit of early discharge from the hospital with easy dosing, no need for monitoring, and home therapy. A DVT critical pathway was established at the U of C in 1998, and LMWH was used off-label for that purpose beginning in 1997. However, it is unclear how quickly the use of LMWH was adopted by the physicians on the general medicine services, or whether there exists a pattern for this adoption.

The design of our study is retrospective in nature. We are interested primarily in the use of LMWH in patients admitted to the general medicine services between January 1, 1997 and February 1, 2001 with a primary and secondary diagnosis related to Venous Thromboembolism, including specific ICD-9 codes.

Using a data abstraction form, we gather the following information: 1) patient demographics, 2) identity of the attending, resident, and interns caring for the patient, 3) whether the patient had any absolute or relative contraindications for receiving LMWH, as delineated by the DVT critical pathway, including insurance status and 4)how the patient was treated for his/her condition. To examine whether the identity of the primary care physician affects whether LMWH is given, we also collect the name of the primary care physician if it is listed on the chart.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
Patients admitted into the general medicine services with a primary or secondary diagnosis related to Venous Thromboembolism.
Thrombosis
Behavioral: Observation
Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
645
January 2019
March 2001   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients admitted to General Medicine Services with a primary or secondary diagnosis related to venous thromboembolism

Exclusion Criteria:

  • Non-General Medicine Services patients
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00203970
10895A
No
Not Provided
Not Provided
University of Chicago
University of Chicago
Not Provided
Principal Investigator: David Meltzer, M.D., Ph.D. University of Chicago
University of Chicago
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP